HUTT to Assess Cardiac Autonomic Nervous Function
Composite Autonomic Scoring Scale and HUTT to Assess Cardiac Autonomic Nervous Function: A Preliminary Study
1 other identifier
observational
1,122
1 country
1
Brief Summary
Autonomic nervous system diseases can cause abnormalities in the circulatory system, leading to malignant arrhythmia and sudden cardiac death. Standardized, operable, and simplified diagnostic indicators are urgently needed to evaluate autonomic nervous function, particularly cardiac autonomic nervous function. The investigators use HUTT in order to provide data support for cardiac autonomic nervous system evaluation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 27, 2023
CompletedStudy Start
First participant enrolled
January 31, 2024
CompletedFirst Posted
Study publicly available on registry
February 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedSeptember 26, 2024
September 1, 2024
1.9 years
December 27, 2023
September 24, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
To find the indicators which are most correlated to the sympathetic and vagus nerves.
The investigators use HUTT and CASS score to find some indicators which are most correlated to the sympathetic and vagus nerves,so that can give data support to the clinical treatments
February 13, 2023 to December 31, 2025
Eligibility Criteria
A total of 1122 (546 males, 576 females) samples were collected according to the inclusion and exclusion criteria.
You may qualify if:
- Vertical tilt test and 24-hour holter electrocardiogram were performed at the same time
- Receive treatment in our hospital.
You may not qualify if:
- Taking benzodiazepines or hypotensive drugs within 24 hours
- Combined with mental illness, severe dementia, serious organ disease
- Severe arrhythmia, deep breathing and poor coordination of Valsaval movements affected the interpretation of results.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Hospital Of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yan Ding, M.D.
Department of Neurology，Xuanwu Hospital，Capital Medical University，Beijing，China.
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Neurology
Study Record Dates
First Submitted
December 27, 2023
First Posted
February 1, 2024
Study Start
January 31, 2024
Primary Completion
December 31, 2025
Study Completion
December 31, 2025
Last Updated
September 26, 2024
Record last verified: 2024-09